Hepatic FASn expression is significantly increased in patients with MASLD.[35] FASn plays a crucial role in hepatic de novo lipogenesis (DNL) and contributes to triglyceride (TG) accumulation in the liver.[36] Due to its strong lipogenic capacity, FASn is considered a promising target for treating metabolic diseases. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatotic liver disease.